Market Place
Sourcing Support
Tisotumab Vedotin Shows Activity In Recurrent/Metastatic HNSCC
03 Jun 2024 //
GLOBENEWSWIRE
Tisotumab Vedotin Active In Recurrent/Metastatic HNSCC Patients
03 Jun 2024 //
BUSINESSWIRE
US FDA grants full approval for Pfizer`s cervical cancer drug
30 Apr 2024 //
REUTERS
TIVDAK® Approved by FDA for Recurrent/Metastatic Cervical Cancer
29 Apr 2024 //
GLOBENEWSWIRE
TIVDAK sBLA Application Accepted for Priority Review by FDA for Cervical Cancer
09 Jan 2024 //
BUSINESSWIRE
TIVDAK sBLA Accepted for Priority Review by FDA for Cervical Cancer
09 Jan 2024 //
GLOBENEWSWIRE
TIVDAK Significantly Prolonged Overall Survival in Patients with Cervical Cancer
22 Oct 2023 //
GLOBENEWSWIRE
Genmab, Seagen say Tivdak cervical cancer trial met overall survival endpoint
05 Sep 2023 //
GLOBENEWSWIRE
Genmab, Seagen Present Data from Tisotumab Vedotin Clinical Development Program
06 Jun 2022 //
BUSINESSWIRE
Genmab and Seagen Present First Data on Tisotumab Vedotin in SCCHN
24 Feb 2022 //
BUSINESSWIRE
Seagen Reports Fourth Quarter and Full Year 2021 Financial Results
09 Feb 2022 //
BUSINESSWIRE
Seagen Reports Third Quarter 2021 Financial Results
28 Oct 2021 //
BUSINESSWIRE
Seagen`s Biologic Tisotumab Vedotin-Tftv Receives Approval in the US
20 Sep 2021 //
FDA
Seagen & Genmab Present Results From Tisotumab Vedotin Combination Therapy
20 Sep 2021 //
BUSINESSWIRE
Seagen to Highlight Research From 16 Presentations Across Multiple Tumor Types
08 Sep 2021 //
BUSINESSWIRE
Genmab, Seattle Genetics eye FDA filing for new cancer med after latest
30 Jun 2020 //
FIERCE PHARMA
Genmab Announces Very Favorable Results from Phase 2 Clinical Trial of Tisotumab
29 Jun 2020 //
GENMAB
Seattle Genetics Announces Positive Topline Results from Phase 2 Clinical
29 Jun 2020 //
SEATTLEGENETICS
Seattle Genetics Announces Positive Results from PH2 Trial of Tisotumab Vedotin
29 Jun 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.